The serum homocystein level and recurrent venous thromboembolism

Petrikov A.S.; Shoĭkhet Ia.N.; Belykh V.I.; Kostiuchenko G.I.; Kotovshchikova E.F.; Peregudova I.G.

doi:https://doi.org/

Petrikov A.S.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

SPIN RSCI: 4612-6452
Scopus AuthorID: 56771302600
ORCID: 0000-0002-6501-3289

Shoĭkhet Ia.N.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

Belykh V.I.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Kostiuchenko G.I.

Nauchno-issledovatel'skiĭ institut terapii Sibirskogo otdeleniia RAMN, Novosibirsk

Kotovshchikova E.F.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Peregudova I.G.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

The serum homocystein level and recurrent venous thromboembolism

Authors:

Petrikov A.S., Shoĭkhet Ia.N., Belykh V.I., Kostiuchenko G.I., Kotovshchikova E.F., Peregudova I.G.

More about the authors

Journal: Journal of Venous Disorders. 2012;6(2): 27‑30

Read: 913 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Petrikov AS, Shoĭkhet IaN, Belykh VI, Kostiuchenko GI, Kotovshchikova EF, Peregudova IG. The serum homocystein level and recurrent venous thromboembolism. Journal of Venous Disorders. 2012;6(2):27‑30. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The present study included 215 patients presenting with recurrent venous thromboembolism (VTE) of whom 97 ones (comprising group 1) experienced a single VTE episode and the remaining 118 suffered two and more such episodes (group 2). The serum homocystein (HC) level was determined in all the patients involved in the study. Group 1 consisted of 42 (43.3%) men and 55 (56.7%) women at the age from 20 to 69 (mean 40.3) years. 64 patients were 45 years of age or younger (25 men and 39 women). Those above the age of 45 years included 17 men and 16 women. Group 2 was comprised of 72 (61.0%) men and 48 (39.0%) women aged from 20 to 69 (mean 41.3) years. 71 patient of group 2 were at the age of 45 years or younger (42 men and 29 women), those above 45 years of age (n = 47) were 30 men and 17 women. The homocystein concentration in the sera equaling 11.0 mcmol/l (X = 9.6+2 SD) was assumed to form the upper limit of normal homocystein level for the residents of the West Siberian region. The analysis of the data obtained in this study demonstrated that the odds ratio (OR) for the development and evolution of recurrent venous thromboembolism is unrelated to the serum homocystein level, age and sex of the patients.

Keywords:

hyperhomocysteinemia

odds ratio

recurrent venous thromboembolic complications

Authors:

Petrikov A.S.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

SPIN RSCI: 4612-6452
Scopus AuthorID: 56771302600
ORCID: 0000-0002-6501-3289

Shoĭkhet Ia.N.

Kafedra fakul'tetskoĭ khirurgii im. I.I. Neĭmarka s kursom khirurgii FPK i PPS

Belykh V.I.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Kostiuchenko G.I.

Nauchno-issledovatel'skiĭ institut terapii Sibirskogo otdeleniia RAMN, Novosibirsk

Kotovshchikova E.F.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Peregudova I.G.

Kafedra propedevtiki vnutrennikh bolezneĭ im. prof. Z.S. Barkagana lechebnogo fakul'teta GBOU VPO "Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdravsotsrazvitiia RF

Close metadata

References:

Den Heijer M., Rosendaal F.R., Blom H.J. et al. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998; 80: 6: 874-877.
Hsu T.S., Hsu L.A., Chang C.J., Sun C.F. et al. Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case - control study. Thromb Res 2001; 102: 5: 387-395.
Monnerat C., Hayoz D. Homocysteine and venous thromboembolism. Schweiz Med Wochenschr 1997; 6: 127: 36: 1489-1496.
Baranova E.I., Bol'shakova O.O. Klinicheskoe znachenie gomotsisteinemii (obzor literatury). Arterial'naya gipertenziya 2004; 10: 1: 12-15.
Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126: 1276-1280.
Undas A., Brozek J., Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94: 907-915.
Mayer E., Jacobsen D., Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
Stein J., Mc Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Int Med 1998; 158: 1301-1306.
Malinow M.R., Bostom A.G., Krauss R.M. Homocysteine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-182.
Harpel P.C., Zhang X., Borth W. Homocysteine and hemostasis: pathogenic mehanisms predisposing to thrombosis. J Nutr 1996; 126: 4: 1285-1289.
Ebbesen L.S. Hyperhomocysteinemia, thrombosis and vascular biology. Cell Mol Biol 2004; 50: 8: 917-930.
Kagan-Ponomarev M.Ya. Pochemu vreden gomotsistein? Angiol i sosud khir 2004; 10: 1: 45-50.
Eichinger S., Stümpflen A., Hirschl M., Bialonczyk C., Herkner K. et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 4: 566-569.
den Heijer M., Willems H.P., Blom H.J., Gerrits W.B., Cattaneo M. et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 1: 109: 1: 139-144.
Shmeleva V.M., Kapustin S.I., Blinov M.N., Papayan L.V. Gipergomotsisteinemiya - znachimyi faktor riska razvitiya arterial'nykh i venoznykh trombozov. Med akad zhurn 2003; 4: 28-34.
Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 18: 293: 19: 2352-2361.
Gusina A.A., Gusina N.B., Zatsepin I.O., Baeshko A.A., Naumchik I.V. Umerennaya gipergomotsisteinemiya kak faktor riska razvitiya venoznykh trombozov v Belarusi. Med novosti 2007; 5: 89-91.
Kostyuchenko G.I., Barkagan Z.S. Diagnostika i metody korrektsii gipergomotsisteinemii v kardiologicheskoi praktike. Posobie dlya vrachei. M 2004; 19.